Journal of Hepatocellular Carcinoma (Mar 2020)
Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really?
Abstract
Dana A Dominguez,1 Xin Wei Wang1,2 1Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; 2Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USACorrespondence: Xin Wei Wang Tel +1 240 760 6858Fax +1 240 541 4444Email [email protected]: Advances in Next-Generation Sequencing (NGS) technology have led to a rapid expansion in the application of “precision medicine,” attempting to personalize therapies and improve outcomes for cancer patients. While these technologies carry great promise, evidence for translation to patient outcomes is lacking. This is especially true in hepatocellular carcinoma (HCC), where multiple factors have hampered efforts to develop effective targeted therapies. We sought to review how application of NGS in HCC has translated to patient outcomes and what barriers stand in the way of further progress.Keywords: next generation sequencing, hepatocellular carcinoma, precision medicine, sequencing
